From PsychonautWiki
Jump to: navigation, search

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Summary sheet: N-Methylbisfluoromodafinil
Molecular structure of N-Methylbisfluoromodafinil
Chemical Nomenclature
Common names N-Methylbisfluoromodafinil, Dehydroxyfluorafinil, "Modafiendz"
Substitutive name N-Methyl-4,4'-difluoro-modafinil
Systematic name 2-{[Bis(4-fluorophenyl)methyl]sulfinyl}-N-methylacetamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 25 - 50 mg
Light 50 - 100 mg
Common 100 - 150 mg
Strong 150 - 200 mg
Heavy 200 mg +
Total 5 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

N-Methyl-4,4'-difluoro-modafinil (also known as N-Methylbisfluoromodafinil, Dehydroxyfluorafinil, and Modafiendz)[1] is an obscure nootropic of the benzhydryl class with no history of research. Although it is closely related on a structural level to adrafinil and modafinil, neither a pharmacological nor a safety-profile similarity should be assumed.


N-methyl-4,4-difluoro-modafinil, or 2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-methylacetamide, is a synthetic molecule of the benzhydryl class. Benzhydryl compounds are comprised of two benzene rings attached to a single carbon molecule. N-methylbisfluoromodafinil contains a fluorine group bound to each benzene ring at R4. It is classified as a sulphinyl benzhydryl molecule, as it also contains a sulphinyl group, a sulfur molecule double-bonded to an oxygen molecule, attached to the carbon of the benzhydryl group. From this sulfur group at R2, an acetamide group is bound at its free carbon through a carbonyl group to an amine group. This terminal amine group is N-substituted with a methyl chain. N-methylbisfluoromodafinil is structurally similar to other benzhydryl stimulants modafinil and fluorafinil; it is the bis-fluoro-N-methyl analog of modafinil.

N-methylbisfluoromodafinil is the bis-fluoro-N-methyl analogue to modafinil; it contains two fluorine groups bound to each benzene ring at carbon 4 and an OH- (hydroxyl) group bound to the amine of modafinil.


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

This compound has not been subject to any research, besides one paper discussing its chemical properties.[2] Even though a pharmacological similarity with modafinil can be assumed, pharmacological similarity to adrafinil and CRL-40,941 seems more likely.[2] This compound should not be assumed safe in any case, until further, though unlikely, research is conducted.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects

  • Stimulation - In terms of its effects on the user's physical energy levels, N-methylbisfluoromodafinil is commonly considered to be stimulating and energetic, but can be considered as much less stimulating when compared to amphetamine. This stimulation encourages physical movement and activities such as running, playing sports, socializing, and/or exercising. The particular style of stimulation which N-methylbisfluoromodafinil presents can result in jaw clenching, teeth grinding, or other involuntary movements comparable to that of traditional stimulants at high doses, but are manifested much less consistently and intensely when compared to amphetamine or cocaine.[citation needed]
  • Dehydration - Dehydration and dry mouth commonly occur due to an increase in motivation to engage in physical activities as well as an increased sense of focus which causes one to forget to drink water.[citation needed]
  • Headaches - In terms of physical discomfort, fluorafanil can cause headaches especially if dehydrated, if you have not eaten food or if you have been sitting in an awkward position for an extended period focused intensely on a task.[citation needed]
  • Appetite suppression - The above components are also accompanied by a suppression of appetite which is usually much less intense in strength in comparison to the appetite suppression experienced with amphetamine.[citation needed]
  • Diarrhea - N-methylbisfluoromodafinil has the tendency to increase the frequency of bowel movements in certain individuals.[citation needed]
  • Increased heart rate[citation needed]
  • Dizziness[citation needed]
  • Nausea[citation needed]

Cognitive effects

Toxicity and harm potential

The toxicity and long-term health effects of recreational N-methylbisfluoromodafinil use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because N-methylbisfluoromodafinil has very little history of human usage. Anecdotal evidence from people who have tried N-methylbisfluoromodafinil within the community suggests that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

The chronic use of N-methylbisfluoromodafinil can be considered as mildly addictive with a low potential for abuse and it does not seem to be capable of causing psychological dependence among certain users due to its lack of euphoria or recreational effects. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of N-methylbisfluoromodafinil develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).[citation needed] N-methylbisfluoromodafinil presents cross-tolerance with all modafanil analogs, meaning that after the consumption of N-methylbisfluoromodafinil all modafinil analogs will have a reduced effect.[citation needed]

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal issues


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

N-methylbisfluoromodafinil is currently a gray area compound within most (if not all) parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analog laws and with intent to sell or consume.

  • United Kingdom - It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[4]

See also


  1. http://www.chemspider.com/Chemical-Structure.29785194.html#synonymsTab
  2. 2.0 2.1 Dowling, G., Kavanagh, P. V., Talbot, B., O’Brien, J., Hessman, G., McLaughlin, G., … Brandt, S. D. (2016). Outsmarted by nooptropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog. Drug Testing and Analysis. https://doi.org/10.1002/dta.2142
  3. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  4. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted